ProBio, a reputable contract development and manufacturing organization (CDMO) with expertise in gene and cell therapy, has recently rolled out its cGMP Adeno-Associated Virus (AAV) manufacturing services at its cutting-edge facility in Hopewell, New Jersey. This strategic move aims to cater to the increasing industry demand for top-notch viral vector production and underscores ProBio’s unwavering commitment to facilitating the progress of groundbreaking gene therapies.
The Hopewell facility has been purposefully constructed to offer comprehensive AAV manufacturing solutions that adhere to global regulatory and quality standards. ProBio’s latest capabilities provide clients with a fully integrated suite of services, encompassing GMP plasmid DNA production, AAV vector manufacturing, and final drug product formulation and aseptic fill/finish, all conveniently housed at a single U.S.-based site. This integrated approach simplifies coordination, minimizes handoffs, and expedites timelines throughout the drug development process.
Allen Guo, the Chief Executive Officer of ProBio, emphasized the company’s commitment to leveraging the new GMP AAV manufacturing platform to help developers overcome intricate manufacturing hurdles swiftly, accurately, and with scientific rigor. The team at Hopewell boasts extensive experience in biologics and viral vector manufacturing, having actively contributed to the development and commercialization of approved therapies. Michael Vreeland, the US Site Head, highlighted the collaborative effort that led to the launch of GMP AAV services, showcasing ProBio’s dedication to offering high-quality, end-to-end solutions to its partners.
Key Takeaways:
– ProBio’s GMP AAV Manufacturing Services feature scalable production options, offering flexibility from 50L to 200L batch sizes to support programs from early clinical to late-phase development.
– The integrated platform at ProBio streamlines the manufacturing process from plasmid production to final drug product fill/finish, reducing complexity and accelerating developers’ path to clinical trials.
– By prioritizing domestic sourcing of key materials, ProBio ensures a robust U.S.-based supply chain, enhancing supply stability and quality for gene therapy developers.
– ProBio’s adoption of digital quality management systems promotes operational efficiency and regulatory compliance, ensuring real-time approval and traceability of critical GMP documentation.
In conclusion, ProBio’s introduction of GMP AAV manufacturing services marks a significant stride in the realm of gene therapy development, solidifying the company’s standing as a trusted partner for innovators in the field. With a focus on agile, phase-appropriate manufacturing solutions, ProBio remains dedicated to adapting to the evolving needs of each unique program, positioning itself as a valuable asset in the advancement of cutting-edge therapeutics.
Tags: formulation, cell therapy, gene therapy, regulatory, biotech
Read more on finance.yahoo.com